Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Nanoparticles Overcome Drug-Resistant Cancer via Sequential Drug Release and Photothermal Therapy
    9 May 2026

    Nanoparticles Overcome Drug-Resistant Cancer via Sequential Drug Release and Photothermal Therapy

    Cancer cells frequently develop the ability to expel anticancer drugs before they can work -- a phenomenon called multidrug resistance (MDR) - which is one of the leading reasons why chemotherapy fails in patients. This research addresses that problem with a fundamentally new strategy: instead of simply increasing drug doses or switching drugs, researchers engineered nanoparticles that first disable the cancer cell's drug-expulsion mechanism, and only then release the anticancer drug.

  • 7 May 2026
    BIZENGRI Receives FDA National Priority Voucher for NRG1+ Cholangiocarcinoma

    Partner Therapeutics, Inc. (PTx), a private, fully integrated biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has awarded a Commissioner’s National Priority Voucher (CNPV) pilot program voucher for BIZENGRI® (zenocutuzumab-zbco) for the treatment of adults with advanced, unresectable or metastatic cholangiocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy.

  • 7 May 2026
    Moderna Publishes Phase 3 Data for Experimental Flu Vaccine mRNA-1010

    Moderna, Inc. announced a publication in the New England Journal of Medicine of the positive Phase 3 study results evaluating mRNA-1010, its vaccine candidate for seasonal influenza. The peer-reviewed article summarizes the safety and efficacy data from Moderna's Phase 3 study (P304) evaluating the relative vaccine efficacy (rVE) of mRNA-1010 against influenza illness compared to a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older.

  • 7 May 2026
    Cipla launches Ciposcillo – A next-generation oscillometer device for respiratory diagnostics

    Cipla announced the launch of Ciposcillo®, an advanced oscillometer designed for accurate and precise assessment of respiratory mechanics. The device enables early diagnosis of obstructive airway diseases such as Chronic Obstructive Pulmonary Disease (COPD) and Asthma. Built on US FDA cleared technology and engineered for Indian clinical practice, Ciposcillo® is CDSCO approved and ISO certified.

  • 7 May 2026
    Brown fat could help protect against cardiovascular disease in obesity
    People with obesity face a significantly increased risk of atherosclerosis, and consequently heart attack and stroke. This elevated risk is largely driven by chronic inflammation in the blood vessels, which is more common in severe obesity.
  • 7 May 2026
    Bariatric surgery more effective than GLP-1 drugs at preventing heart attacks, stroke and death in older adults

    Metabolic and bariatric surgery offers significantly greater long-term protection against heart attack, stroke and death than widely-used GLP-1 drugs in older adults with obesity and diabetes, according to new real-world analysis study* presented today at the annual meeting of the American Society for Metabolic and Bariatric Surgery (#ASMBS2026).

  • 7 May 2026
    Saveetha College of Pharmacy collaboration with IPGA organized a webinar titled Pharmacy – World of Opportunities

    Saveetha College of Pharmacy (SIMATS), Chennai, jointly in collaboration with the Indian Pharmaceutical Graduates' Association (IPGA) successfully organized a webinar titled “Pharmacy – World of Opportunities” on May 4, 2026. 

  • 6 May 2026
    Lilly’s Omvoh Shows 4-Year Durable Disease Clearance in Ulcerative Colitis

    New long-term data from Eli Lilly and Company (NYSE: LLY) show patients with moderately to severely active ulcerative colitis (UC) treated with Omvoh (mirikizumab-mrkz) achieved durable disease clearance through four years of continuous treatment. In the LUCENT-3 open-label extension study, 63.5% of Omvoh-treated patients who achieved disease clearance at one year sustained it at four years.

  • 6 May 2026
    Johnson & Johnson Announces Pivotal Clinical Study Results for a New Soft-Tissue Surgical Robotic System
    Johnson & Johnson announced results from the first clinical study of the investigational OTTAVA™ Robotic Surgical System – a prospective, multicenter clinical study evaluating the safety and performance of the system in Roux-en-Y gastric bypass procedures.
  • 6 May 2026
    JNJ announces Phase 2b data from two studies evaluating JNJ-4804

    Johnson & Johnson announced Phase 2b data from two studies evaluating JNJ-4804, an investigational co-antibody therapy targeting both interleukin-23 (IL-23) and tumor necrosis factor-alpha (TNF-α), in patients with moderately to severely active ulcerative colitis (UC) and Crohn’s disease (CD) that is refractory to systemic therapies.1,2 The late-breaking presentations from the DUET-UC and DUET-CD studies were among the 32 company-sponsored abstracts being presented at Digestive Disease Week (DDW) 2026.

Subscribe to Pharma News